IRIS - Res&Arch Institutional Research Information System - Research & Archive

FRANCISCI, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.642
EU - Europa 5.730
AS - Asia 2.213
Continente sconosciuto - Info sul continente non disponibili 13
SA - Sud America 10
AF - Africa 6
OC - Oceania 2
Totale 15.616
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.608
IE - Irlanda 1.437
IT - Italia 991
UA - Ucraina 980
SG - Singapore 923
SE - Svezia 881
HK - Hong Kong 532
VN - Vietnam 318
FI - Finlandia 306
CN - Cina 295
RU - Federazione Russa 288
DE - Germania 284
GB - Regno Unito 165
FR - Francia 138
AT - Austria 55
CH - Svizzera 46
TR - Turchia 46
BE - Belgio 39
NL - Olanda 31
KR - Corea 29
PL - Polonia 29
UZ - Uzbekistan 27
CA - Canada 24
CZ - Repubblica Ceca 17
EU - Europa 12
GR - Grecia 12
LB - Libano 9
RO - Romania 9
ES - Italia 8
MX - Messico 8
IR - Iran 7
BR - Brasile 4
SK - Slovacchia (Repubblica Slovacca) 4
AR - Argentina 3
ID - Indonesia 3
IL - Israele 3
IN - India 3
TW - Taiwan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CL - Cile 2
JP - Giappone 2
NO - Norvegia 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BD - Bangladesh 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
GH - Ghana 1
IQ - Iraq 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
MY - Malesia 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
QA - Qatar 1
RS - Serbia 1
TH - Thailandia 1
Totale 15.616
Salva come PNG Salva come JPEG
Città #
Dublin 1.435
Chandler 1.247
San Mateo 738
Singapore 692
Boardman 552
Hong Kong 528
Jacksonville 480
Santa Clara 435
Altamura 409
Medford 373
Princeton 372
Dong Ket 316
Lawrence 301
Wilmington 272
Perugia 256
Ann Arbor 240
Andover 229
Des Moines 132
Ashburn 103
Saint Petersburg 96
Dearborn 93
Beijing 85
Redmond 77
Norwalk 74
Falls Church 69
Woodbridge 68
Los Angeles 59
San Paolo di Civitate 58
Helsinki 55
Izmir 43
Shanghai 40
Brussels 38
Houston 37
New York 35
Rome 28
Seoul 28
Munich 27
Redwood City 26
Philadelphia 24
Den Haag 23
Moscow 23
Vienna 22
Frankfurt Am Main 16
Auburn Hills 14
Dallas 14
Milan 14
Ottawa 14
Florence 12
Chicago 11
Lappeenranta 11
Nanning 10
San Diego 10
Timisoara 9
Bastia umbra 8
London 8
Nanjing 8
Seattle 8
Toronto 8
Zhengzhou 8
Amsterdam 7
Cambridge 7
Lausanne 7
Bologna 6
Espoo 6
Kunming 6
Tappahannock 6
Brno 5
Foligno 5
Kiev 5
Olomouc 5
Paris 5
Piediluco 5
Amelia 4
Bratislava 4
Clifton 4
Collazzone 4
Fairfield 4
Falkenstein 4
Frankfurt am Main 4
Guangzhou 4
Hefei 4
Inwood 4
Jinan 4
Nanchang 4
Ningbo 4
Brescia 3
Catanzaro 3
Detroit 3
Edinburgh 3
Giugliano In Campania 3
Kocaeli 3
Kraków 3
Ludwigshafen 3
Madrid 3
Menlo Park 3
Nagold 3
Napoli 3
Padova 3
Shenzhen 3
Terni 3
Totale 10.593
Salva come PNG Salva come JPEG
Nome #
Amfotericina B in complessi lipidici nel trattamento della Leishmaniosi viscerale in un paziente immunodepresso 98
Concentrazioni ossee e plasmatiche di moxifloxacina in pazienti operati di protesi di ginocchio 96
A case of severe cdfepime-related neutropenia in a 15-year-old patient 92
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 90
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 89
Nocardiosi cerebrale primaria in un paziente immunocompetente 87
Acute cytomegalovirus meningomyelitis in an immunocompetent patient. 87
Trattamento dell'epatite cronica C con IFN-2b e ribavirina in pazienti non responder o relapser a solo IFN-: dati preliminari sulla nostra esperienza. 86
Mielite da Toxoplasma gondii in un paziente con AIDS 86
The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of gpbar1 rescues mice from murine colitis 85
Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial 85
A randomized trial comparing the introduction of ritonavir on indinavir in 1251 nucleoside-experienced patients with advanced HIV infection 84
Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers. 84
Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study 84
Risk factors for acute parenterally transmitted viral hepatitis: a 20-year study. 84
L'infezione da Clostridium Difficile in pazienti ospedalizzati: uno studio retrospettivo. XXIX Congresso AMCLI 2000, 83
Acute fatal necrotizing hemorrhagic encephalitis caused by Epstein-Barr virus in a young adult immunocompetent man 83
Malattie Infettive trasmesse da Zecca in Umbria: indagine epidemiologica 82
Prima indagine sieroepidemiologica sulla circolazione del virus Toscana in Umbria. Atti congresso di malattie Infettive 81
Encefalite emorragica e infezione disseminata da Epstein barr virus: descrizione di un caso clinico con outcome fatale. 81
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 80
Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection 80
Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: evaluation of some risk factors. 79
Target di autoimmunità endocrina in corso di terapia con IFN-alfa in pazienti con epatite cronica da HCV. 30°congr.naz. SISMIP, Ferrara 6-9 ottobre 1999 78
Long term treatment of a variant form of autoimmune chronic active hepatitis with cyclosporine: a case report. 78
Tolerability of different postexposure prophylaxis regimens in occupational and non occupational exposures to HIV: the italian registry 77
Epidemiological, clinical and therapeutical aspects of HIV/HCV coinfection in a series of HIV seropositive Umbrian patients. 76
Accelerate Pheno™ system in sepsis by Gram-negative pathogens: four months of hospital experience 74
Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. 73
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59 adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. 72
Epidemiologia, clinica e terapia della coinfezione HIV-HCV nell'esperienza umbra. 71
Malattie da virus a DNA- Citomegalovirosi 71
epidemiologia e clinica della coinfezione HIV-HCV nell'esperienza umbra 70
Acute appendicitis due to Cytomegalovirus in an apparently immunocompetent patient: a case report 70
Anal Cancer Screening for Diagnosis and Treatment of Anal Squamous Intraepithelial Lesions in HIV-positive MSM patients 70
Esperienza con Efavirenz nei pazienti con infezione da HIV seguiti presso la Clinica di Malattie Infettive di Perugia 69
HIV type 1 infection, and not short-term HAART, indice endothelial dysfunction. 69
Modificazioni epidemiologiche delle epatiti virali acute in Umbria; 30 anni di osservazione. Congresso Soc. It. Mal. Inf. 68
A case of rhombencephalitis caused by Listeria monocytogenes successfully treated with linezolid 68
Programmed granulocyte neutrophil death in patients at different stages of HIV infection 68
Prevalence, incidence and clinical outcome of hepatitis B virus and hepatitis C virus hepatitis in patients undergoing allogeneic hematopoietic stem cell transplantation between 2001 and 2004. 68
Acute infection with parvovirus B19 manifesting as brain stem encephalitis. 68
La terapia HAART nell'esperienza della clinica di Malattie Infettive di Perugia 67
Semiquantitative PCR in the diagnosis of HIV infection: correlation to clinical stage and serological status. 67
Correlation of preS antigens and clinical status during chronic hepatitis B virus infection. 67
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. 67
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients 67
Effects of antiretroviral therapy on lipid and immunovirological profile: Focus on proprotein convertase subtilisin/kexin 9 67
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI 67
Identificazione dei soggetti a più alto rischio di infezione disseminata da HCMV tra i riceventi un trapianto renale. 30° congr.naz. SISMIP Ferrara 6-9 ottobre 1999 66
Metodo rapido di estrazione dell'RNA da C. neoformans. 66
Infezioni da bacilli gram-negativi aerobi- Bartonellosi 65
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder(INR) HIV-1-infected patients treated with HAART 65
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 65
Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature 65
Patologie neurologiche AIDS-defining in era HAART e Pre-HAART: nuovi scenari 64
ANALISI DELLA FUNZIONALITÀ RENALE IN PAZIENTI CON INFEZIONE DA HIV NAIVE TRATTATI CON TENOFOVIR. STUDIO CASO-CONTROLLO. 64
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppression 64
Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy. 64
Cytomegalovirus colitis in a patient with recent failure of kidney transplant. 64
Identification of a possible ancestor of the subtype A1 HIV Type 1 variant circulating in the former Soviet Union 64
Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty 64
HBV-DNA, HBeAg/anti-HBe serological status in hepatitis B chronic individuals from central Italy. 63
Biochemical markers of bone turnover and calcium dietary intake evaluation in HIV-infected patients 63
A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV patients on stable antiretroviral therapy 63
Impact of Antimicrobial Stewardship Interventions on Appropriateness of Surgical Antibiotic Prophylaxis: How to Improve 63
SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione 63
Bone and serum concentrations of moxifloxacin in patients undergoing total knee arthroplasty 62
Monocyte dysfunction in patients with acquired immunodeficiency syndrome (AIDS) versus Cryptococcus neoformans 62
Combined ganciclovir and foscarnet therapy of recurrent cytomegalovirus and aggressive retinitis in AIDS 62
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 61
Monitoraggio virologico dell'infezione da HCMV in pazienti riceventi trapianto di midollo osseo allogenico. 30°congr. Naz. SISMIP, Ferrara 6-9 ottobre 1999 61
Acute transverse myelitis and hepatitis C virus 60
Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS 60
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 60
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virologiccal failure 60
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir,efavirenz or lopinavir/ritonavir in the Italian ARCA cohort 59
Alterazioni in HCMV end-organ disease in the course of highly active antiretroviral therapy (HAART). 59
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 59
Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis 59
Suboptimal indinavir concentrations in cerebrospinal fluid 58
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 58
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy 58
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 58
Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis 58
Meningite cronica da HSV-2 in un adulto immunocompetente: descrizione di un caso clinco 57
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 57
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 57
Nitric oxide protects againist HIV gp 120 endothelial injury. 57
Antiretroviral drug susceptibility among drug-naive adults with chronic or recent HIV infectionin Umbria region 57
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. 57
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. 56
Inhibition of fungicidal activity of polymorphonuclear leukocytes from HIV-infected patients by interleukin (IL)-4 and IL-10 56
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 56
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 56
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. 56
Liposomal Amphotericin B for visceral Leishmaniasis in a kidney allograft patient 55
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance, which salvage regimen? 55
Variazioni del cariotipo elettroforetico ed analisi RAPD di isolati clinici ed ambientali di C. neoformans. 54
Tipranavir exhibits different effects on opportunistic pathogenic fungi. 54
Totale 6.862
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.174
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020756 0 0 0 0 0 64 190 20 201 124 28 129
2020/20212.550 13 146 124 154 775 172 155 41 274 127 184 385
2021/20222.973 94 514 78 173 108 54 47 897 70 104 380 454
2022/20234.897 418 975 74 362 351 476 24 195 1.797 6 161 58
2023/20241.801 104 203 89 41 16 16 411 32 204 74 336 275
2024/20251.778 49 536 124 164 690 215 0 0 0 0 0 0
Totale 16.559